Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.58 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | GPR183 | P32249 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14190917 | 1.00 | ACHE (0.58) | ACHECYP1A1CYP1A2CYP1B1CYP2D6 | |
| SCHEMBL14190944 | 0.90 | ACHE (0.64) | ACHECYP1A1CYP1A2CYP1B1CYP2D6 | |
| SCHEMBL4378530 | 0.90 | ACHE (0.64) | ACHECYP1A1CYP1A2CYP1B1CYP2D6 | |
| SCHEMBL14190916 | 0.82 | GAA (0.61) | ACHECYP1A1CYP1B1ALDH1A1GAA | |
| SCHEMBL4380520 | 0.82 | GAA (0.61) | ACHECYP1A1CYP1B1ALDH1A1GAA | |
| SCHEMBL13039675 | 0.81 | KDM4E (0.59) | ACHECYP1A1CYP1A2CYP1B1CYP2D6 | |
| SCHEMBL13039668 | 0.79 | L3MBTL1 (0.61) | ACHECYP1A1CYP1A2CYP1B1CYP2D6 | |
| SCHEMBL4376236 | 0.78 | HPGD (0.67) | ACHECYP1A1CYP1A2CYP1B1CYP2D6 | |
| SCHEMBL14190943 | 0.78 | HPGD (0.67) | ACHECYP1A1CYP1A2CYP1B1CYP2D6 | |
| SCHEMBL13636194 | 0.77 | GPR183 (0.56) | ACHEGAAMAPTGPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421071-B1 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-11-18 | — | — | EP | claimed |
| EP-1421071-B1 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20080113968-A1 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-7208497-B2 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2007-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113968-A1 | Substituted piperazines and diazepanes | HRH3, HRH4, HRH1 | ACHE 1650/4885CYP1A1 1278/4885CYP1A2 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.